# Boston Scientific Corp (BSX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/boston-scientific-corp/ JSON: https://steadybase.io/company/boston-scientific-corp.json Checked Nov 10, 2026. Latest filing read: Nov 2, 2026.

## Company

- Legal name: BOSTON SCIENTIFIC CORP
- Ticker: BSX (NYSE)
- SEC CIK: 0000885725
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Marlborough, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: bostonscientific.com
- Investor relations: https://investors.bostonscientific.com/
- LinkedIn: https://www.linkedin.com/company/boston-scientific
- Next earnings date: Feb 10, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $20.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.html
- Operating income: $3.6B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.html
- Net income: $2.9B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.html
- SG&A: $6.9B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.html
- Employees: 59,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.html
- Shares outstanding: 1,449,473,222 as of Oct 29, 2026 (10-Q filed Nov 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/0000885725-26-000070-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm

## Business

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $20.1B | $3.6B | $2.9B | $6.9B |
| Dec 31, 2024 | $16.7B | $2.6B | $1.8B | $6.0B |
| Dec 31, 2023 | $14.2B | $2.3B | $1.6B | $5.2B |
| Dec 31, 2022 | $12.7B | $1.6B | $698.0M | $4.5B |
| Dec 31, 2021 | $11.9B | $1.2B | $1.0B | $4.4B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/boston-scientific-corp.json

## Officers and directors

- Mike Mahoney, Chairman and chief executive officer, Boston Scientific. Source: 8-K filed Oct 28, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/earningsrelease_live.htm
- Michael F. Mahoney, Chairman, President & CEO. Source: Form 4 filed Aug 5, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826006950/0001225208-26-006950-index.htm
- Jonathan Monson, EVP and CFO. LinkedIn: https://linkedin.com/in/jon-monson-3021aa5. Source: Form 4 filed Aug 11, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826007062/0001225208-26-007062-index.htm
- Padraig Andrew O'Connor, EVP, Global Operations. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826007620/0001225208-26-007620-index.htm
- Emily Woodworth, SVP, Global Controller and CAO. Source: Form 4 filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826007084/0001225208-26-007084-index.htm
- Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology. Source: Form 4 filed Aug 3, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826006881/0001225208-26-006881-index.htm
- Miriam O'Sullivan, SVP, Chief HR Officer. LinkedIn: https://www.linkedin.com/in/miriam-o-sullivan-8942721a. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826002138/0001225208-26-002138-index.htm
- Vance R. Brown, EVP, GC and Corp. Secretary. LinkedIn: https://linkedin.com/in/vance-brown-693a018. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/885725/000122520826002132/0001225208-26-002132-index.htm
- Emily M. Woodworth, Senior Vice President, Global Controller and Chief Accounting Officer. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Cheryl Pegus, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- David Habiger, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- David S. Wichmann, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Edward J. Ludwig, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Ellen M. Zane, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Jessica L. Mega, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Susan E. Morano, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- Jonathan R. Monson, Named in proxy. Source: DEF 14A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm
- Joseph M. Fitzgerald, Named in proxy. Source: DEF 14A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm
- Padraig A. O'Connor, Named in proxy. Source: DEF 14A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm

## Recent 8-K events

- Oct 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/bsx-20261028.htm
- Oct 7, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm
- Sep 23, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000061/bsx-20260921.htm
- Sep 8, 2026: Item 1.05, Material cybersecurity incident. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000059/bsx-20260907.htm
- Aug 26, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000056/bsx-20260826.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/bsx-20260729.htm
- Jul 27, 2026: Item 2.05, Costs associated with exit or disposal activities (restructuring). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm
- May 18, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000042/bsx-20260518.htm
- May 18, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000041/bsx-20260518.htm
- May 5, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000036/bsx-20260430.htm

## Insider trades (Form 4)

- Aug 25, 2026: Susan E. Morano (Director) bought 2,040 shares, about $100,409. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826007337/0001225208-26-007337-index.htm
- Aug 5, 2026: David C. Habiger (Director) bought 2,100 shares, about $99,939. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826007031/0001225208-26-007031-index.htm
- Aug 4, 2026: David C. Habiger (Director) bought 1,182 shares, about $56,892. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826006951/0001225208-26-006951-index.htm
- Aug 3, 2026: Michael F. Mahoney (Chairman, President & CEO) bought 186,240 shares, about $9.0M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826006950/0001225208-26-006950-index.htm
- Jul 31, 2026: Edward J. Ludwig (Director) bought 5,000 shares, about $227,400. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826006882/0001225208-26-006882-index.htm
- May 20, 2026: Cheryl Pegus (Director) bought 1,770 shares, about $99,987. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826005548/0001225208-26-005548-index.htm
- May 20, 2026: Edward J. Ludwig (Director) bought 3,580 shares, about $202,914. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826005547/0001225208-26-005547-index.htm
- May 20, 2026: David C. Habiger (Director) bought 4,450 shares, about $251,110. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826005546/0001225208-26-005546-index.htm
- Feb 2, 2026: Michael F. Mahoney (Chairman, President & CEO) sold 160,901 shares, about $15.0M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520826001156/0001225208-26-001156-index.htm
- Dec 1, 2025: Arthur C. Butcher (EVP& Grp Pres, MedSurg & APAC) sold 17,313 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825009597/0001225208-25-009597-index.htm
- Nov 6, 2025: Ellen M. Zane (Director) sold 12,891 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825008997/0001225208-25-008997-index.htm
- Nov 3, 2025: Joseph Michael Fitzgerald (EVP & Group Pres, Cardiology) sold 50,000 shares, about $5.0M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825008911/0001225208-25-008911-index.htm
- Oct 28, 2025: Ellen M. Zane (Director) sold 12,891 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825008761/0001225208-25-008761-index.htm
- Oct 1, 2025: Joseph Michael Fitzgerald (EVP & Group Pres, Cardiology) sold 50,000 shares, about $4.9M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825008180/0001225208-25-008180-index.htm
- Sep 2, 2025: Joseph Michael Fitzgerald (EVP & Group Pres, Cardiology) sold 50,000 shares, about $5.3M. Source: https://www.sec.gov/Archives/edgar/data/885725/000122520825007716/0001225208-25-007716-index.htm

## What management said

- "This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients" Mike Mahoney, chairman and chief executive officer, Boston Scientific (8-K filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/earningsrelease_live.htm

## Latest filings

- 8-K filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/bsx-20261028.htm
- 10-K filed Feb 17, 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
- 10-Q filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/bsx-20260930.htm
- DEF 14A filed Mar 18, 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/